Reduced Venetoclax Exposition to Seven Days of Azacitidine Is Efficient in Treatment-Naïve Patients with Acute Myeloid Leukemia
Christophe Willekens, Samy Chraïbi, Justine Decroocq, Benjamin Carpentier, Delphine Lebon, Sarah Bonnet, Nicolas Gauthier, Arnaud Pagès, Matteo Dragani, Sabine Khalife‐Hachem, Jean‐Baptiste Micol, Florence Pasquier, Stefan Wickenhauser, Véronique Saada, Véronique Vergé, Ahmadreza Arbab, Christophe Marzac, Laurent Pascal, Damien Roos‐Weil, Éric Jourdan, Didier Bouscary, Stéphane de Botton
Abstract
International audience
Topics & Concepts
VenetoclaxMedicineAzacitidineInternal medicineMyeloid leukemiaVenHazard ratioOncologyDiscontinuationGastroenterologyLeukemiaConfidence intervalChronic lymphocytic leukemiaBiologyComputer securityBiochemistryDNA methylationComputer scienceGeneGene expressionAcute Myeloid Leukemia ResearchHistone Deacetylase Inhibitors ResearchMultiple Myeloma Research and Treatments